CA
NZ
UK
AU
IND
US
Weave (NYSE: WEAV)has completed its acquisition of TrueLark, an AI-based front-desk automation and receptionist platform, advancing its broader strategy of integrating artificial intelligence into healthcare communications. The deal represents a step forward in Weave’s focus on expanding its offerings for small and medium-sized healthcare …
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW), a company specializing in the development and commercialization of medicines targeting infectious diseases, announced its financial results for the first quarter ended March 31, 2025. The results highlighted continued revenue growth and product traction, particularly in the …
CureVac N.V. (NASDAQ: CVAC), a global biopharmaceutical leader in messenger RNA (mRNA) innovation, has secured another key legal victory in its ongoing patent litigation against BioNTech SE. The European Patent Office (EPO) has upheld the validity of CureVac’s European patent EP 4 023 755 …
AbCellera Biologics Inc. (Nasdaq: ABCL) has received a No Objection Letter (NOL) from Health Canada, authorizing the company to proceed with a Phase 1 clinical trial for its investigational drug candidate ABCL635. The study is focused on addressing moderate-to-severe vasomotor symptoms (VMS), commonly referred …
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company focused on treating Obstructive Sleep Apnea (OSA), announced its financial results for the first quarter of 2025, reporting revenue of €1.1 million, down from €1.2 million in the same quarter last year.
RadNet, Inc. (NASDAQ:RDNT), a national leader in outpatient diagnostic imaging has reported its financial results for the first quarter of 2025, tempered by weather-related disruptions. At the same time, the company has raised its full-year financial guidance and made strategic moves to enhance its …
argenx SE [Euronext & Nasdaq: ARGX], a biotechnology firm focused on autoimmune diseases, announced its financial results for the first quarter of 2025, alongside updates on its expanding pipeline and regulatory progress. The company reported $790 million in global net product sales from VYVGART® …
Evotec SE (NASDAQ: EVO) has reported its financial results for Q1 2025, showcasing a solid start to the year despite challenges in the drug discovery market. The company achieved revenues of €200 million, a 4% decline compared to Q1 2024, aligning with their expectations. …
DexCom, Inc. (Nasdaq:DXCM)has reported its financial performance for the first quarter of 2025, with notable revenue growth, expanded product reach, and key regulatory milestones that signal continued momentum for the glucose monitoring technology leader.
BriaCell Therapeutics Corp., a clinical-stage biotechnology company, has presented new data from its ongoing pivotal Phase 3 trial of Bria-IMT™, an investigational immunotherapy for metastatic breast cancer (MBC). The study, titled BRIA-ABC (NCT06072612), explores how specific biomarkers might predict patient response to the Bria-IMT …
Please wait processing your request...